Biocircuits Corp., of Sunnyvale, Calif., completed the first sale andshipment of its IOS immunodiagnostic testing systems, whichincorporates a test instrument and disposable assay cartridges.

Biopool International Inc., of Ventura, Calif., received FDAapproval to market the Bioclot Protein S Assay, which helps diagnoseand identify those at risk for developing clotting disorders. Protein Sis a naturally occurring anticoagulant in blood.

Coulter Corp., of Miami, received a license to manufacture andmarket the blood-screening product, the Coulter HIV-1 p24 AntigenAssay. The product is intended for use by blood and plasmacollection centers to screen samples for HIV. Current tests detectHIV in 22 days while the Coulter test can provide results in 16 days,the company said. Ortho Diagnostic Systems Inc., a Raritan, N.J.,subsidiary of Johnson & Johnson, will market the test.

Endogen Inc., of Cambridge, Mass., acquired most of the operatingassets of T Cell Diagnostics, a Needham, Mass., subsidiary of T CellSciences Inc., for $2.9 million. The $2.9 million consists of $1.9million in convertible debt payable over five years and a combinationof cash and a short-term note as buyout of $1 million in T CellDiagnostics' obligations under a lease. T Cell Sciences retainedownership of the TRAx diagnostic line and related technology.

Matritech Inc., of Newton, Mass., signed a marketing and productpurchase agreement covering the Matritech NMP22 Test Kit withUroCor Inc., of Oklahoma City. The product, for detection of bladdercancer, is under regulatory review. Terms were not disclosed.

Molecular Biosystems Inc., of San Diego, received notificationfrom European regulatory authorities that the ultrasound contrastagent Albunex (Infoson in Europe) was recommended for approval inthe European Union.

Quidel Corp., of San Diego, received "waived" testing status for itsQuickVue In-Line One-Step Strep A Test from the Centers forDisease Control and Prevention. Waived Status, for tests that useunprocessed samples, expands by 25,000 the number of doctors'offices where the test can be performed, the company said. Quidelsaid it is the first company to receive such status for an infectiousdisease test.

Sonus Pharmaceuticals, of Bothell, Wash., said results presented ona Phase III study of EchoGen Emulsion for use as an ultrasoundcontrast agent showed overall contrast enhancement and facilitatedvisualization of blood flow or lesions was seen in 94 percent ofEchoGen patients. Average duration of contrast enhancement wasmore than 15 minutes, and significant grayscale enhancement wasseen in 25 percent of patients, with an average duration of 12minutes.

* Syncor International Corp., of Chatsworth, Calif., and Diatide Inc.,of Londonderry, N.H., entered into a non-exclusive distributionagreement for Hong Kong and China. Syncor immediately can begindistributing Diatide's nuclear imaging agent, Techtide P829, asomatostatin-receptor binding peptide for detecting and localizingtumors.

* Xenometrix Inc., of Boulder, Colo., introduced the AMAX (AmesII Mutagenic Assay by Xenometrix) system, a next-generation assayfor use in testing compounds for potential carcinogenic activity.

(c) 1997 American Health Consultants. All rights reserved.